Navigation Links
Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
Date:10/18/2011

GREENWOOD VILLAGE, Colo., Oct. 18, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has demonstrated in an IRB approved, randomized, placebo controlled, double-blinded proof of concept study, that low dose intranasal danazol has an impact on allergic rhinitis, a clinical condition in which increases in vascular permeability and edema are hallmark signs.

The study was not powered to show statistical significance as an effective treatment for rhinitis but rather intended to investigate the effect of danazol in a clinical condition associated with vascular permeability and edema.  After a 7 day washout period, patients were treated twice a day for 14 days with either placebo (n=10) or low-dose intranasal danazol (n=10) and assessed two times per day (AM and PM) using the validated Total Nasal Symptom Score (TNSS).  A larger decrease in TNSS indicates a greater improvement in symptoms.  A comparison of the PM score showed a strong trend toward efficacy, with a total mean change between washout and treatment of -2.39 for the treatment group compared to -0.34 for the placebo (p=0.10).  

"The pathogenesis of edema is very similar in different diseases.  The fact that low dose danazol could decrease edema in this setting is exciting, as it may indicate a similar impact of Optina™ on DME (Diabetic Macular Edema)," said Dr. Vaughan Clift, Chief Regulatory Officer of Ampio Pharmaceuticals, noting that "an oral formulation of low dose danazol (Optina™) is already the subject of a placebo-controlled, dose ranging trial in DME, the results of which are expected in Q2 2012."

About Optina(TM) (danazol)

Danazol is a weak androgen approved at high do
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
2. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
3. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
4. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
5. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
6. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
7. Ampio Pharmaceuticals Set to Join Russell 3000 Index
8. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
9. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
10. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Glenmark Pharmaceuticals S.A. (GPSA), a ... (GPL), announces the discovery and initiation of IND ... GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 ... Research Centre located in La Chaux-de-Fonds, ... Glenmark,s innovative BEAT antibody technology platform which facilitates ...
(Date:8/19/2014)... Aug. 19, 2014  The Alabama Supreme Court, in a ... sue drug makers who mislead doctors into believing that prescription ... case is Weeks v. Wyeth, and the decision came after ... same case last year. Heninger Garrison Davis attorneys Lew ... in the case, Danny Weeks . The ...
(Date:8/19/2014)... 2014 Minimally Invasive Devices Inc. (MID), a ... announced today that Mitsubishi Corporation has formally agreed to ... in Japan . MID anticipates that ... Japan in the second half of 2015. ... for Karl Storz GMBH & Co. (endoscopic instruments and ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... DATATRAK International, Inc.(OTCQX: DATA), a technology and services ... trials industry, today announced the signing of two new ... award includes a multi-site, five-year study and demonstrates a ... , "We are pleased that our partnership ...
... CHEYENNE, Wyo., Aug. 24 The Wyoming Department of Health ... program, a component of its innovative Total Health Record initiative. ... community and the Wyoming EqualityCare (EC) Healthy Together program, as ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/2008 ...
Cached Medicine Technology:Research-Based Biopharmaceutical Company Awards Trials to DATATRAK 2Research-Based Biopharmaceutical Company Awards Trials to DATATRAK 3Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3
(Date:8/20/2014)... Botanica Day Spa has ... new and popular stem cell line from Pevonia®, ... wrinkles and naturally repairs the skin. The spa ... service by offering clients a complimentary dermaplaning session ... , Pevonia® continues to be a global leader ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Leaving the car at home and ... good for your health, a new study indicates. Researchers ... found that 76 percent of men and 72 percent of ... percent of women used public transit, and 14 percent of ... Those who drove to work weighed more and had higher ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, ... blocks. , Urbini, a new collection of versatile baby gear ... jogger to its lineup. , The Avi has been ... by the latest racing styles and a set of features ... offers a swift, smooth ride on runs, power-walks and causal ...
(Date:8/20/2014)... D.C. (PRWEB) August 20, 2014 ... received a five-year, $1.24 million Science Education Partnership ... Health to support NAHN’s collaborative project with the ... in Health Careers. , This collaborative NIH R25 ... for cultural and linguistic diversity among health professionals ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... BUFFALO, N.Y. -- The University at Buffalo announced today a ... and family to establish the Jacobs Institute, which will support ... of heart and vascular diseases. , ... was made in honor of Lawrence D. Jacobs, M.D., a ...
... 13 Market competition is,mounting to win ... most highly,qualified clinical investigators. Companies that develop ... their studies win an advantage in,bringing their ... white paper "Recruiting and Retaining,High-Quality Clinical Investigators" ...
... for recent disasters, WASHINGTON, June 13 The ... with relief efforts for,the victims of flooding and tornadoes ... West Virginia, the Red Cross is present,with vast amounts ... of,thousands of meals., Already, more than 1,400 Red ...
... Long and costly product,development cycles make it essential ... to the development of compounds with,the greatest potential ... and earlier into the new product process in ... development cycle,time, focus resources for greatest impact and ...
... lead to diagnostic urine test for 10% of men with ... traits of an aggressive type of prostate cancer that occurs ... been identified in hopes of finding a way to diagnose ... the Michigan Center for Translational Pathology at the University of ...
... June 2008: The TRAF1/C5 locus on chromosome 9 has ... diseases including type 1 diabetes and systemic lupus erythematosus ... 2008, the Annual Congress of the European League Against ... Factor-receptor associated factor 1) and C5 (complement component 5) ...
Cached Medicine News:Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 2Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 3Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 4Health News:American Red Cross Issues Appeal for Disaster Relief Fund 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2Health News:Researchers ID Traits of Aggressive Prostate Cancer 2Health News:Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases 2
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
... Finnpipette BioControl multichannel has ... as the single channel ... fits all seven multichannel ... tip cone modules. Both ...
Medicine Products: